Infantile hemangioma
Conditions
Interventions
Group 1 :0.5% Timolol Maleate Cream
Sponsors
Shanghai Xuhui Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female healthy subjects aged 18-55 years; 2. Weight: male >= 50 kg, female >= 45 kg; 19 kg/m2 <= body mass index (BMI) <= 28 kg/m2; 3. Subjects who have no pregnancy plan and voluntarily take effective contraceptive measures during the test period to 3 months after the last administration, and have no plan to donate sperm or eggs; 4. The subject fully understands the purpose, nature, method and possible adverse reactions of the test, volunteers as a subject, and signs an informed consent; 5. Those who have no skin damage or scars or skin diseases at the medication site.
Exclusion criteria
Exclusion criteria: 1. Those who are known to be allergic to timolol maleate, or to other ß-blockers or have a history of severe allergies, or allergic constitution; 2. Suffering from malignant tumors and diseases of the heart, endocrine, blood, liver, immunity, metabolism, urinary system, lungs, nervous system, rheumatism/joints, spirit, kidney, etc., which the researchers consider unsuitable for participation Participants in this clinical trial; 3. Severe heart disease or asthma, severe respiratory disease; 4. Have a history of atopic dermatitis; 5. Received vaccination within 1 month (30 days) before screening; 6. Those who have used clinical trial drugs within 3 months (90 days) before screening, are participating in or plan to participate in other clinical trials during this study; 7. Those who have used any prescription drugs, non-prescription drugs or Chinese herbal medicines within 14 days before screening; 8. Those who have a history of drug abuse or who are positive for drug abuse screening; 9. Hepatitis B surface antigen, hepatitis C virus antibody, Treponema pallidum antibody positive, HIV test positive; 10. Physical examination, vital signs, laboratory tests (blood routine, urine routine, blood biochemistry), 12-lead electrocardiogram results and chest X-ray examination judged by clinicians to be abnormal and have clinical significance; 11. The subject may not be able to complete the study due to other reasons or the researcher believes that it should not be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax for Timolol; | — |
Countries
China
Contacts
Public ContactJingying Jia
Shanghai Xuhui Central Hospital
Outcome results
None listed